Stockscreener 앱 받기
4.71
70.65%
1.95
시간 외 거래:
4.07
-0.64
-13.59%
전일 마감가:
$2.76
열려 있는:
$3.155
하루 거래량:
50.71M
Relative Volume:
198.22
시가총액:
$89.90M
수익:
-
순이익/손실:
$-40.19M
주가수익비율:
-2.009
EPS:
-2.3444
순현금흐름:
$-38.49M
1주 성능:
-67.06%
1개월 성능:
-55.69%
6개월 성능:
-40.15%
1년 성능:
-40.75%
1일 변동 폭
$2.8602
$6.64
1주일 범위
$2.66
$14.89
52주 변동 폭
$2.66
$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
4.71 | 77.87M | 0 | -40.19M | -38.49M | -2.3444 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Ladenburg Thalmann | Buy |
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study - whbl.com
Elicio Confident In Phase III Plan Despite Phase II Miss In Pancreatic Cancer - Citeline News & Insights
Do phase II data Amplify KRAS PDAC promise for Elicio? - BioWorld News
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Yahoo Finance
Top Midday Decliners - Moomoo
ELTX Maintained by HC Wainwright & Co. -- Price Target Raised to $23 - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Benzinga
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc. - GlobeNewswire
Elicio nosedives on phase 2 data for pancreatic cancer asset (ELTX:NASDAQ) - Seeking Alpha
Elicio crashes on Phase II miss for cancer vaccine, pins hopes on post-hoc signal - FirstWord PHARMA
Elicio Therapeutics reports Phase 2 AMPLIFY-7P results - grafa.com
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study - The Pharma Letter
Rodman & Renshaw raises Elicio Therapeutics price target to $17.50 By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Elicio Therapeutics stock rating at buy - Investing.com
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 - BioSpace
Why is Elicio Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
Why is Elicio Therapeutics stock collapsing today? - Investing.com
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal - marketscreener.com
Elicio Therapeutics Reports Phase 2 AMPLIFY-7P Results and Refines Phase 3 Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer – Minichart - Minichart
Elicio Unveils Phase 2 ELI-002 Results and Phase 3 Plan - TipRanks
Elicio’s pancreatic cancer trial misses primary endpoint By Investing.com - Investing.com South Africa
Elicio Therapeutics Shares Plunge After Pancreatic Cancer Study Misses Main Goal (ELTX) - Yahoo Finance
Elicio’s pancreatic cancer trial misses primary endpoint - Investing.com UK
Elicio (Nasdaq: ELTX) Phase 2 ELI-002 refocuses on R0 patients - Stock Titan
Elicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright - TipRanks
Elicio Therapeutics stock tumbles after trial misses endpoint By Investing.com - Investing.com South Africa
Elicio Therapeutics stock tumbles after trial misses endpoint - Investing.com
Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer - TradingView
Pancreatic cancer trial finds DFS gain in surgery patients, Phase 3 planned - Stock Titan
Elicio Therapeutics Price Target Announced at $27.00/Share by B. Riley Securities - Moomoo
(ELTX) Risk Channels and Responsive Allocation - Stock Traders Daily
B. Riley Initiates Elicio Therapeutics at Buy With $27 Price Target - marketscreener.com
Elicio Therapeutics (ELTX) Falls 4.8% as Biotech Volatility Persists — Key Support in FocusOn Balance Volume - newsline.com
ELTX Stock Price, Quote & Chart | ELICIO THERAPEUTICS INC (NASDAQ:ELTX) - ChartMill
Elicio Therapeutics Announces Publication in Peer-Reviewed - GlobeNewswire
Elicio cancer immunotherapy triggers months-long immune memory in animals - Stock Titan
(ELTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ELTX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $17 - GuruFocus
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Elicio Therapeutics (ELTX) Holds Near Resistance as Therapeutic Pipeline Momentum BuildsAD Line Divergence - newsline.com
Elicio Therapeutics (ELTX) Climbs +8.72% — Resistance at $10.47 in Focus 2026-05-20Leveraged ETF Flow - The Legal Advocate
Elicio Therapeutics (ELTX) Q1 2026 Earnings Miss: EPS $-0.65 vs $-0.47 ExpectedEPS Consistency Score - The Legal Advocate
Liquidity Mapping Around (ELTX) Price Events - Stock Traders Daily
MIT: Big strides in cancer detection and treatment from the tiniest technologies - marketscreener.com
TradingKey - TradingKey
Elicio Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout - ChartMill
Elicio Therapeutics, Inc. 1Q 2026: Net income $(11.8M), EPS $(0.65) — 10-Q Summary - TradingView
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):